332 related articles for article (PubMed ID: 28827416)
1. Mixed Formulation of Conventional and Pegylated Meglumine Antimoniate-Containing Liposomes Reduces Inflammatory Process and Parasite Burden in Leishmania infantum-Infected BALB/c Mice.
Reis LES; Fortes de Brito RC; Cardoso JMO; Mathias FAS; Aguiar Soares RDO; Carneiro CM; de Abreu Vieira PM; Ramos GS; Frézard FJG; Roatt BM; Reis AB
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827416
[TBL] [Abstract][Full Text] [Related]
2. Association of water extract of green propolis and liposomal meglumine antimoniate in the treatment of experimental visceral leishmaniasis.
Ferreira FM; Castro RA; Batista MA; Rossi FM; Silveira-Lemos D; Frézard F; Moura SA; Rezende SA
Parasitol Res; 2014 Feb; 113(2):533-43. PubMed ID: 24292604
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Efficacy of a Mixed Formulation of Conventional and PEGylated Liposomes Containing Meglumine Antimoniate, Combined with Allopurinol, in Dogs Naturally Infected with Leishmania infantum.
Dos Santos CCP; Ramos GS; De Paula RC; Faria KF; Moreira POL; Pereira RA; Melo MN; Tafuri WL; Demicheli C; Ribeiro RR; Azevedo EG; Do Monte-Neto R; Da Silva SM; Frézard F
Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32284386
[TBL] [Abstract][Full Text] [Related]
4. Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis.
Azevedo EG; Ribeiro RR; da Silva SM; Ferreira CS; de Souza LE; Ferreira AA; de Oliveira E Castro RA; Demicheli C; Rezende SA; Frézard F
Expert Opin Drug Deliv; 2014 Oct; 11(10):1551-60. PubMed ID: 24962630
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis.
Cardoso JMO; Brito RCF; Mathias FAS; Reis LES; Vieira JFP; Ostolin TLVDP; Andrade HM; Ramos GS; Frézard F; Aguiar-Soares RDO; Roatt BM; Reis AB
Mol Immunol; 2022 Jan; 141():70-78. PubMed ID: 34814056
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of aminosidine administered alone or in combination with meglumine antimoniate for the treatment of experimental visceral leishmaniasis caused by Leishmania infantum.
Gangneux JP; Sulahian A; Garin YJ; Derouin F
J Antimicrob Chemother; 1997 Aug; 40(2):287-9. PubMed ID: 9301998
[TBL] [Abstract][Full Text] [Related]
7. Novel methods for the encapsulation of meglumine antimoniate into liposomes.
Frézard F; Michalick MS; Soares CF; Demicheli C
Braz J Med Biol Res; 2000 Jul; 33(7):841-6. PubMed ID: 10881061
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic of meglumine antimoniate encapsulated in phosphatidylserine-liposomes in mice model: A candidate formulation for visceral leishmaniasis.
Borborema SET; Osso Junior JA; Tempone AG; de Andrade Junior HF; do Nascimento N
Biomed Pharmacother; 2018 Jul; 103():1609-1616. PubMed ID: 29864949
[TBL] [Abstract][Full Text] [Related]
9. Hepatic fibropoiesis in dogs naturally infected with Leishmania (Leishmania) infantum treated with liposome-encapsulated meglumine antimoniate and allopurinol.
Castro RS; de Amorim IFG; Pereira RA; Silva SM; Pinheiro LJ; Pinto AJW; Azevedo EG; Demicheli C; Caliari MMV; Mosser DM; Michalick MSM; Frezard FJG; Tafuri WL
Vet Parasitol; 2018 Jan; 250():22-29. PubMed ID: 29329619
[TBL] [Abstract][Full Text] [Related]
10. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.
Gangneux JP; Sulahian A; Garin YJ; Farinotti R; Derouin F
Antimicrob Agents Chemother; 1996 May; 40(5):1214-8. PubMed ID: 8723469
[TBL] [Abstract][Full Text] [Related]
11. Meglumine Antimoniate (Glucantime) Causes Oxidative Stress-Derived DNA Damage in BALB/c Mice Infected by Leishmania (Leishmania) infantum.
Moreira VR; de Jesus LCL; Soares RP; Silva LDM; Pinto BAS; Melo MN; Paes AMA; Pereira SRF
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320726
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effect of reference antileishmanial agents in murine visceral leishmaniasis due to Leishmania infantum.
Buffet PA; Garin YJ; Sulahian A; Nassar N; Derouin F
Ann Trop Med Parasitol; 1996 Jun; 90(3):295-302. PubMed ID: 8758143
[TBL] [Abstract][Full Text] [Related]
13. Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate.
Ribeiro RR; Moura EP; Pimentel VM; Sampaio WM; Silva SM; Schettini DA; Alves CF; Melo FA; Tafuri WL; Demicheli C; Melo MN; Frézard F; Michalick MS
Antimicrob Agents Chemother; 2008 Jul; 52(7):2564-72. PubMed ID: 18458133
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of combined therapy with liposome-encapsulated meglumine antimoniate and allopurinol in treatment of canine visceral leishmaniasis.
da Silva SM; Amorim IF; Ribeiro RR; Azevedo EG; Demicheli C; Melo MN; Tafuri WL; Gontijo NF; Michalick MS; Frézard F
Antimicrob Agents Chemother; 2012 Jun; 56(6):2858-67. PubMed ID: 22411610
[TBL] [Abstract][Full Text] [Related]
15. The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.
Moosavian SA; Fallah M; Jaafari MR
Exp Parasitol; 2019 May; 200():30-35. PubMed ID: 30898544
[TBL] [Abstract][Full Text] [Related]
16. Experimental evaluation of second-line oral treatments of visceral leishmaniasis caused by Leishmania infantum.
Gangneux JP; Dullin M; Sulahian A; Garin YJ; Derouin F
Antimicrob Agents Chemother; 1999 Jan; 43(1):172-4. PubMed ID: 9869587
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis.
Faraut-Gambarelli F; Piarroux R; Deniau M; Giusiano B; Marty P; Michel G; Faugère B; Dumon H
Antimicrob Agents Chemother; 1997 Apr; 41(4):827-30. PubMed ID: 9087498
[TBL] [Abstract][Full Text] [Related]
18. Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages.
Borborema SE; Schwendener RA; Osso JA; de Andrade HF; do Nascimento N
Int J Antimicrob Agents; 2011 Oct; 38(4):341-7. PubMed ID: 21783345
[TBL] [Abstract][Full Text] [Related]
19. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate.
Barroso PA; Marco JD; Calvopina M; Kato H; Korenaga M; Hashiguchi Y
J Antimicrob Chemother; 2007 Jun; 59(6):1123-9. PubMed ID: 17439977
[TBL] [Abstract][Full Text] [Related]
20. Behavior of two Leishmania infantum strains-evaluation of susceptibility to antimonials and expression of microRNAs in experimentally infected J774 macrophages and in BALB/c mice.
Silva SC; Silva DF; Almeida TC; Perasoli FB; da Silva ATP; da Silva GN; Rezende SA
Parasitol Res; 2018 Sep; 117(9):2881-2893. PubMed ID: 29943317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
